Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the diabetic neuropathy market grown in recent years?
In the past few years, the diabetic neuropathy market has experienced a robust growth. The market size is anticipated to escalate from $5.79 billion in 2024 to $6.27 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%. The substantial growth witnessed during the historic period is due to factors such as an increase in the global incidence of diabetes, heightened awareness and diagnosis, advancements in care for diabetics, surge in healthcare spending, investments in research and development, and efforts towards patient education.
How is the diabetic neuropathy market size expected to evolve during the forecast period?
The market for diabetic neuropathy is projected to experience significant expansion in the coming years, growing to a valuation of $9.3 billion by 2029, with a compound annual growth rate (CAGR) of 10.4%. The predicted growth during the forecast period can be linked to progress in neuroimaging, patient-centered care models, increased clinical trials, a consistent rise in diabetes incidence, precision treatment methodologies, the growth of regenerative medicine, and patient aid and advocacy initiatives. Key trends during the forecast period involve cooperative initiatives in medical studies, digital health interventions, progress in diagnostic technology, neuroprotective treatments, individualized treatment plans, and the inclusion of artificial intelligence.
Get your diabetic neuropathy market report here!
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
Which key drivers are propelling the diabetic neuropathy market’s growth?
The diabetic neuropathy market is predicted to grow due to the increasing occurrence of diabetes. Diabetes is a chronic ailment where the body fails to efficiently utilize and store glucose (a kind of sugar). It happens when the body either doesn’t produce adequate insulin (a hormone responsible for balancing blood sugar) or fails to use the insulin appropriately. When individuals with diabetes suffer various types of nerve damage it is often classified as diabetic neuropathy, each resulting in distinct symptoms. For example, in August 2022, the International Diabetes Federation published the IDF Diabetes Atlas report. The Federation, a Belgium-based global diabetes community including over 230 national diabetes associations, reported that in 2021, diabetes caused approximately 6.7 million deaths, which is equal to one death every five seconds. Currently, 537 million adults (aged 20-79) or 1 in 10 people are living with diabetes. This figure is predicted to rise to 643 million by 2030 and 783 million by 2045. As a result, the increasing occurrence of diabetes is propelling the growth of the diabetic neuropathy market.
What are the market segments in the diabetic neuropathy industry?
The diabetic neuropathy market covered in this report is segmented –
1) By Disorder: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy
2) By Drug Class: Analgesics, Anti-Depressants, Anti-Convulsants, Other Drug Classes
3) By Treatment: Drug Treatment, Radiotherapy, Physiotherapy, Other Treatments
4) By Distribution Channel: Online Distribution, Offline Distribution
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Peripheral Neuropathy: Distal Symmetric Neuropathy, Mononeuropathy, Polyneuropathy
2) By Autonomic Neuropathy: Cardiovascular Autonomic Neuropathy, Gastrointestinal Autonomic Neuropathy, Genitourinary Autonomic Neuropathy
3) By Proximal Neuropathy: Diabetic Amyotrophy, Lumbosacral Plexus Neuropathy
4) By Focal Neuropathy: Cranial Neuropathy, Cervical Radiculopathy, Other Focal Neuropathies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9057&type=smp
Which leading companies are shaping the growth of the diabetic neuropathy market?
Major companies operating in the diabetic neuropathy market include Pfizer Inc., Eli Lilly and Company, Daiichi Sankyo Company Limited, Johnson & Johnson, Depomed Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Lupin Limited, Novartis AG, Boehringer Ingelheim, Regenacy Pharmaceuticals Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Zydus Cadila, Biogen Inc., Genentech Inc.
What key trends are currently impacting the diabetic neuropathy market’s development?
Leading firms in the diabetic neuropathy market are spearheading the advancement of innovative products, including the neuromodulation therapy device, to broaden the spectrum of treatment solutions for individuals afflicted with chronic pain due to diabetic neuropathy. These devices offer non-invasive treatments by adjusting nerve impulse to allay pain, enhance nerve function, and induce healing for patients with diabetic nerve injuries. For example, in January 2024, Neuralace Medical, Inc., a US company specializing in non-pharmaceutical pain management therapies, achieved approval from the US-based Food and Drug Administration (FDA) for their Axon Therapy for Chronic Painful Diabetic Neuropathy. With this therapeutic tool explicitly tailored to address chronic painful diabetic neuropathy (CPDN), the evolution of neuromodulation techniques significantly broadens the available pain management options for patients living with this disease. The FDA’s approval accentuates the safety and effectiveness of the Axon Therapy device, catalyzing Neuralace’s efforts towards commercialization and increasing availability of effective treatments to CPDN patients.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9057
Which geographic areas are influencing the growth of the diabetic neuropathy market?
North America was the largest region in the diabetic neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the diabetic neuropathy market during the forecast period. The regions covered in the diabetic neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Neurology Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report
Neurology Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report
Neurostimulation Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neurostimulation-devices-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
